MedTrace Logo

To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects

NCT01175564 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2013-02-06

No results posted yet for this study

Summary

The purpose of this study is to assess safety, tolerability and pharmacokinetics after a single and repeated oral doses of TC-5214 (S-mecamylamine) in healthy male Japanese subjects.

Conditions

  • Healthy

Interventions

DRUG

TC-5214

Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet

DRUG

Placebo

Placebo tablet, single dose and 6 days repeated dose

Sponsors & Collaborators

Principal Investigators

  • Hans Eriksson · AstraZeneca R&D Sodertalje, SE-151 85 Sodertalje, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2010-09-30
Completion
2010-09-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01175564 on ClinicalTrials.gov